12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Other News

Cadence neurology news

Cadence said in its 4Q11 earnings that during the quarter it restructured and reduced headcount by 17 (7%) to 227 to focus resources on commercialization of Ofirmev IV acetaminophen....

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >